Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 5, 2003, Pages 1310-1316

  Caffo, Orazio ^a   Fellin, Gianni ^a   Graffer, Umberto ^a   Valduga, Francesco ^a   Bolner, Andrea ^a   Luciani, Lucio ^a   Tomio, Luigi ^a   Galligioni, Enzo ^a  

^a SANTA CHIARA HOSPITAL   (Italy)

Author keywords

Bladder cancer; Cisplatin; Gemcitabine; Radiotherapy; Transurethral resection

Indexed keywords

BIOLOGICAL ORGANS; BIOPSY; CHEMOTHERAPY; COMPUTERIZED TOMOGRAPHY; RADIOTHERAPY; SURGERY; TOXICITY;

RADIOSENSITIZERS;

ONCOLOGY;

ANTINEOPLASTIC AGENT; CISPLATIN; GEMCITABINE;

ACUTE DIARRHEA; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INFILTRATION; CANCER LOCALIZATION; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC COLONOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTESTINE PERFORATION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR BIOPSY;

EID: 0345689453     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00763-6     Document Type: Article

References (27)

1. Shipley W.U., Zietman A.L., Kaufman D.S., et al. Invasive bladder cancer Treatment strategies using transurethral surgery, chemotherapy and radiation therapy with selection for bladder conservation . Int J Radiat Oncol Biol Phys. 39:1997;937-943.
2. Shipley W.U., Winter K.A., Kaufman D.S., et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy Initial results of Radiation Therapy Oncology Group 89-03 . J Clin Oncol. 16:1998;3576-3583.
3. Tester W., Porter A., Asbell S., et al. Combined modality program with possible organ preservation for invasive bladder carcinoma Results of RTOG protocol 85-12 . Int J Radiat Oncol Biol Phys. 25:1993;783-790.
4. Tester W., Caplan R., Heaney J., et al. Neoadjuvant combined modality program with possible organ preservation for invasive bladder cancer Results of Radiation Therapy Oncology Group phase II trial 8802 . J Clin Oncol. 14:1996;119-126.
5. Fellin G., Graffer U., Bolner A., et al. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. Br J Urol. 80:1997;44-49.
6. Shipley W.U., Kaufman D., Zehr E.M., et al. Selective bladder preservation by combined modality protocol treatment Long-term outcomes of 190 patients with invasive bladder cancer . Urology. 60:2002;62-67.
7. Rodel C., Grabenbauer G.G., Kuhn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer Long-term results . J Clin Oncol. 20:2002;3061-3071.
8. Pollera C.F., Ceribelli A., Crecco M., et al. Weekly gemcitabine in advanced bladder cancer A preliminary report from a phase I study . Ann Oncol. 5:1994;182-184.
9. Lorusso V., Pollera C.F., Antimi M., et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer. 34:1998;1208-1212.
10. Moore M.J., Tannock I.F., Ernst D.S., et al. Gemcitabine A promising new agent in the treatment of advanced urothelial cancer . J Clin Oncol. 15:1997;3441-3445.
11. Stadler W.M., Kuzel T., Roth B., et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 15:1997;3394-3398.
12. Bergman A.M., Ruiz van Haperen V.W., Veerman G., et al. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 2:1996;521-530.
13. von der Maase H., Andersen L., Crino L., et al. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium A phase II clinical trial . Ann Oncol. 10:1999;1461-1465.
14. Moore M.J., Winquist E.W., Murray N., et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer A phase II trial of the National Cancer Institute of Canada Clinical Trials Group . J Clin Oncol. 17:1999;2876-2881.
15. Kaufman D., Raghavan D., Carducci M., et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 18:2000;1921-1927.
16. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer Results of a large, randomized, multinational, multicenter phase III study . J Clin Oncol. 18:2000;3068-3077.
17. Shewach D.S., Lawrence T.S. Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol. 23:1996;65-71.
18. Lawrence T.S., Chang E.Y., Hahn T.M., et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys. 34:1996;867-872.
19. Caffo O., Fellin G., Graffer U., et al. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire. Cancer. 78:1996;1089-1097.
20. Fields M.T., Eisbruch A., Normolle D., et al. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′- deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys. 47:2000;785-791.
21. Goor C, Scallet P, Van Meerbeek J, et al. A phase II study combining gemcitabine with radiotherapy in stage III NSCLC. Ann Oncol 1996;7(Suppl. 5):481P.
22. Eisbruch A., Shewach D.S., Bradford C.R., et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer A phase I trial and intracellular drug incorporation study . J Clin Oncol. 19:2001;792-799.
23. Smith DC, Montie JE, Sandler HS, et al. Pilot trial of concurrent gemcitabine (GEM) and radiotherapy as a bladder preservation strategy. Proc Am Soc Clin Oncol 2000;19:360a.
24. Eisbruch A, Shewach DS, Urba S, et al. Phase I trial of radiation (RT) concurrent with low-dose gemcitabine (GEM) for head and neck cancer: High mucosal and pharyngeal toxicity. Proc Am Soc Clin Oncol 1997;16:386a.
25. Vokes EE, Leopold KA, Hernodon JE, et al. A CALGB randomized phase II study of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy in stage IIIB non-small cell carcinoma: Feasibility data (CALGB study # 9431). Proc Am Soc Clin Oncol 1997;16:455a.
26. Blackstock A.W., Bernard S.A., Richards F., et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 17:1999;2208-2212.
27. Perez C.A. Uterine cervix. Perez C.A., Brady L.W. Principles and practice of radiation oncology. 3rd ed: 1997;1733-1834 Lippincott-Raven, Philadelphia.